Portal de investigación
CARACTERIZACIÓN DE LOS INHIBIDORES EN PACIENTES CON DIAGNÓSTICO DE HEMOFILIA ADQUIRIDA
Datos básicos
- Código:
- SET-INM-2010-01
- Protocolo:
- SET-INM-2010-01
- EUDRACT:
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
- 2014
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry
Van den Berg, M; (...); Ljung, R
Meeting Abstract. 10.1182/blood-2018-99-114518. 2018
A MODIFICATION OF CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY TO EXPLORE NEW COFACTORS OF ACTIVATED PROTEIN C IN PLASMA
Martos, L.; (...); Navarro Rosales, S.
Meeting Abstract. 10.1016/S0049-3848(14)50233-2. 2014
A NEW INTRONIC MUTATION CAUSES AN ABERRANT SPLICING IN THE ANK1 GENE
Liquori, A.; (...); Cervera, J., V
Meeting Abstract. 2018
A simplified assay for quantification of circulating activated protein C levels
Medina, P.; (...); Espana, F.
Article. 2013
A simplified assay for the quantification of circulating activated protein C
Martos L; (...); Medina P
Article. 10.1016/j.cca.2016.05.025. 2016
a2-Macroglobulin is a significant in vivo inhibitor of activated protein C and low levels of APC:a2M are associated with venous thromboembolism
Navarro S; (...); Medina P
Article. 2018
Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A
García-Dasí M; (...); García-Talavera JA
Article. 10.1111/hae.12618. 2015
-
PlumX Metrics
- Citations
- Citation Indexes: 49
- Policy Citations: 2
- Clinical Citations: 1
- Captures
- Readers: 91
- Mentions
- News Mentions: 1
Adherence to prophylaxis in adult patients with severe haemophilia A
Bonanad, S; (...); Alvarez, M
Meeting Abstract. 2019
Adherence to prophylaxis in adult patients with severe haemophilia A
Bonanad, S; (...); Alvarez, MP
Article. 10.1111/hae.14039. 2020
alpha(2)-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: alpha M-2 Levels Are Associated with Venous Thromboembolism
Martos, L; (...); Medina, P
Article. 10.1055/s-0038-1629902. 2018
Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.
Article. 10.1002/ccr3.1206. 2017
Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders
Civaschi E; (...); European Haematology Association - Scientific Working Group on Thrombocytopenias
Article. 10.1111/bjh.13458. 2015
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.
Paciullo F; (...); Gresele P
Article. 10.3324/haematol.2019.227876. 2020
Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.
Vila V; (...); España F
Article. 10.1111/hae.12044. 2013
Association of haplotypes (H) 1 and 3 of the endothelial protein c receptor gene (PROCR) with venous thromboembolism
Bonet, Elena; (...); Espana, Francisco
Article. 10.1016/j.thromres.2012.08.027. 2012
Association of haplotypes (H) 1 and 3 of the endothelial protein C receptor gene (PROCR) with venous thromboembolism
Navarro, S.; (...); Medina, P.
Article. 2013
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy
Querol, Felipe; (...); Bonanad Boix, Santiago
Meeting Abstract. 10.1182/blood-2019-125651. 2019
Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades
Nijdam A; (...); PedNet and CANAL study groups
Letter. 10.3324/haematol.2014.115709. 2015
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders
Orsini, S; (...); European Hematology Association - Scientific Working Group (EHA-SWG) on thromboc
Article. 10.3324/haematol.2016.160754. 2017
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A.
Tiede A; (...); Persson P
Article. 10.1055/s-0039-3400745. 2020
Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.
Moret, A; (...); Bonanad, S
Letter. 10.1016/j.thromres.2019.06.015. 2019
CLINICAL AND MOLECULAR CHARACTERIZATION BY SEQUENCING OF NEW GENERATION OF PATIENTS AFFECTED BY FIBRINOGEN CONGENITAL DEFICIENCIES
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2019
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
COMBINED DEFICIENCY OF PROTEIN C, PROTEIN S AND ANTITHROMBIN IN PATIENTS WITH MESENTERIC OR PORTAL VENOUS THROMBOSIS WITH OR WITHOUT HEPATIC CIRRHOSIS
Martos, L.; (...); Espana, F.
Meeting Abstract. 10.1016/S0049-3848(14)50197-1. 2014
Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method
Cabrera, N.; (...); Aznar, J. A.
Article. 2013
Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.
Cabrera N; (...); Aznar JA
Article. 10.1111/hae.12203. 2013
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Challenges, questions and opportunities with regard to the new relationship between clinical practice and the haemostasis laboratory: the path towards personalized medicine.
Article. 10.1097/MBC.0000000000001091. 2021
CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION
Liquori, A.; (...); Gomez-Segui, I
Meeting Abstract. 2019
Demographic and baseline data from patients with hemophilia and inhibitors enrolled in the feiba global outcomes ("FEIBA GO") study
Windyga, J; (...); Escuriola-Ettingshausen, C
Meeting Abstract. 2019
DESCRIPTIVE STUDY ON HAEMOPHILIA EXPERIENCE ACQUIRED IN A REFERENCE CENTRE
De la Puerta, R.; (...); Haya Guaita, S.
Meeting Abstract. 2019
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
Fischer K; (...); Königs C
Article. 10.1182/bloodadvances.2023011442. 2024
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
DIAGNOSIS AND MANAGEMENT OF HEMARTHROSIS AND HAEMOPHILIC ARTHROPATHY USING UNIFIED CLINICAL AND ULTRASOUND CRITERIA: PRELIMINARY RESULTS
Chimeno-Hernandez, A; (...); Querol, F
Meeting Abstract. 2021
DIFFERENT CLINICAL MANIFESTATION OF DYSFIBRINOGENEMIAS ASSOCIATED TO THE MUTATION ARG275 IN EXON 8 OF FGG GENE
Mesa, E.; (...); Bonanad, S.
Meeting Abstract. 10.1016/S0049-3848(14)50268-X. 2014
Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.
Jimenez-Yuste, Victor; (...); Paez, Antonio
Letter. 10.1111/hae.14453. 2022
Efficacy of factor IX Grifols(®) in surgery: experience of an international multicentre retrospective study.
Pérez-Garrido R; (...); Rescia V
Letter. 10.1111/j.1365-2516.2012.02919.x. 2012
Emerging viral infections--a potential threat for blood supply in the 21st century.
de Mendoza C; (...); Soriano V
Article. 2012
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
EVALUATION OF ISTH-BAT IN CONGENITAL PLATELET DISORDERS: CLINICAL, LABORATORY AND MOLECULAR CORRELATION
Bastida, J. M.; (...); Rivera, J.
Meeting Abstract. 2019
Evaluation of the effect on endogenous factor VIII activity (FVIII: C) after recombinant von Willebrand factor (rVWF) administration during the elective surgery study in patients with severe von Willebrand disease (VWD)
Mamaev, A; (...); Peyvandi, F
Meeting Abstract. 2018
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
Eckhardt CL; (...); Fijnvandraat K
Article. 10.1182/blood-2013-02-483263. 2013
Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC; (...); van den Berg HM
Article. 10.1056/NEJMoa1208024. 2013
-
-
PlumX Metrics
- Citations
- Citation Indexes: 383
- Patent Family Citations: 1
- Policy Citations: 5
- Clinical Citations: 1
- Captures
- Readers: 251
- Mentions
- News Mentions: 2
- References: 1
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Moret A; (...); Bonanad S
Article. 10.1007/s11239-020-02065-z. 2020
FEIBA GLOBAL OUTCOME (FEIBA GO) STUDY: REAL-WORLD DATA IN PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS
Hermans, C; (...); Windyga, J
Meeting Abstract. 2021
FEIBA GO STUDY: REAL-WORLD BLEEDING FREQUENCY IN INHIBITOR PATIENTS ON PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES
Ettingshausen, CE; (...); Crea, R
Meeting Abstract. 2018
Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study
Sánchez-Guiu I; (...); Lozano ML
Article. 10.1186/s13023-014-0213-6. 2014
Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions
Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta
Meeting Abstract. 2024
Haplotypes of the endothelial protein C receptor gene and circulating protein C levels
Martos, L.; (...); Medina, P.
Article. 2013
Haplotypes of the endothelial protein C receptor gene and circulating protein C levels
Martos, Laura; (...); Espana, Francisco
Article. 10.1016/j.thromres.2012.08.026. 2012
Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Lissitchkov T; (...); Páez A
Article. 10.1111/hae.12148. 2013
Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A
Letter. 10.1111/hae.12622. 2015
HYPERPROTEIEMIA AND HYPERFIBRINOLYSIS INCREASED IN PREANESHTESIA STUDY
Guinot Segarra, M.; (...); Luch Garcia, R.
Meeting Abstract. 2019
Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency
Martos, L; (...); Spanish Soc Thrombosis Haemostasis
Article. 10.1055/s-0039-1692440. 2019
Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency
Martos, Laura; (...); Espana, Francisco
Article. 10.1016/j.thromres.2012.08.029. 2012
Immune Tolerance Induction in A Patient with Severe Haemophilia A and Factor VIII Inhibitors
Freiria Alberte, C.; (...); Haya Guaita, S.
Meeting Abstract. 2017
IMPACT OF INITIATION OF PROPHYLAXIS, SYNOVITIS AND FUNCTIONALITY ON JOINT HEALTH IN PATIENTS WITH HEMOPHILIA
Chimeno, A.; (...); Bonanad Boix, S.
Meeting Abstract. 2023
Increased circulating dna, calprotectin and mieloperoxidase, as neutrophil extracellular trap markers, are risk factors for deep vein thrombosis
Martos, L.; (...); Medina, P.
Meeting Abstract. 2015
INCREASED LEVELS OF FREE CIRCULATING DNA AND DNASE 1 ACTIVITY IN PLASMA IS ASSOCIATED WITH AN INCREASED RISK OF VENOUS THROMBOEMBOLISM
Oto, J.; (...); Medina, P.
Meeting Abstract. 2019
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A
Article. 10.1111/hae.12439. 2014
Is on-demand treatment effective in patients with severe haemophilia?
Aznar JA; (...); Moret A
Article. 10.1111/j.1365-2516.2012.02806.x. 2012
Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; (...); Aznar JA
Article. 10.1111/j.1365-2516.2012.02858.x. 2012
Large deletion in the Factor VIII gene (F8) involving segmental duplications in int22h shows no haematological phenotype in female carriers, but may be embryonic lethal in males.
Casaña P; (...); MARTINEZ, F.
Letter. 10.1111/j.1365-2141.2012.09092.x. 2012
Less common hemorrhagic coagulopathies in women.
Article. 10.1097/MBC.0000000000000990. 2020
Management of acquired hemophilia A: results from the Spanish registry.
Mingot-Castellano ME; (...); Marco P
Article. 10.1182/bloodadvances.2021004626. 2021
Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds
Andersson, NG; (...); PedNet Haemophilia Res Fdn
Article. 10.3324/haematol.2018.209619. 2019
Moderate and severe haemophilia in Spain: An epidemiological update
Aznar, JA; (...); Lopez, MF
Letter. 10.1111/hae.13462. 2018
Modification of a thrombin generation test to identify new cofactors of the protein C pathway in plasma
Martos, L.; (...); Navarro, S.
Meeting Abstract. 2015
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients
Borràs N; (...); Corrales, I
Article. 10.3324/haematol.2017.168765. 2017
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm
Batlle J; (...); Vidal F
Article. 10.1160/TH15-04-0282. 2016
-
-
PlumX Metrics
- Citations
- Citation Indexes: 33
- Policy Citations: 4
- Captures
- Readers: 32
- Mentions
- News Mentions: 1
Monitoring drug activity of dabigatran and rivaroxaban by thrombin generation using the calibrated automated thrombinoscope
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2015
Mortality caused by intracranial bleeding in non-severe hemophilia A patients
Loomans, JI; (...); Fijnvandraat, K
Article. 10.1111/jth.13693. 2017
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.
Moret, A; (...); Bonanad, S
Article. 10.1007/s11239-019-01911-z. 2019
Nosocomial fungemia by Candida auris: First four reported cases in continental Europe
Ruiz Gaitan, Alba Cecilia; (...); Peman, Javier
Article. 10.1016/j.riam.2016.11.002. 2017
Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction
Lozano ML; (...); Rivera J
Article. 10.1182/blood-2015-11-683102. 2016
Patient and treatment related factors and inhibitor development after 50 exposure days in patients with non-severe hemophilia A-preliminary data of a nested case-control study
Abdi, A; (...); INSIGHT Study Grp
Meeting Abstract. 2019
PATIENT WITH CONGENITAL AFIBRINOGENEMIA AND PERIPHERAL ARTERIAL THROMBOSIS. THERAPEUTIC ANTITHROMBOTIC MANAGEMENT BASED ON MONITORING
Moscardo, A.; (...); Valles, J.
Meeting Abstract. 10.1016/S0049-3848(14)50371-4. 2014
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megias-Vericat, J. E.; (...); Poveda Andres, J. L.
Article. 10.1016/j.thromres.2022.06.001. 2022
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
Peyvandi, F; (...); Sytkowski, A
Article. 10.1111/jth.14313. 2019
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
PK-guided switch from standard half-life to extended half-life factor VIII products
Megias-Vericat, JE; (...); Iorio, Alfonso
Meeting Abstract. 2020
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study
Haya, S; (...); Casana, P
Letter. 10.1111/hae.13660. 2019
Prophylactic treatment in hemophilic patients with inhibitors.
Article. 10.1097/MBC.0000000000000823. 2019
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings
Parra Lopez R; (...); Rendo P
Article. 10.1160/TH14-09-0760. 2015
Quality of thawed plasma inactivated with methylene blue after 48-hour storage
Balaguer A; (...); Sanz MÁ
Letter. 10.1016/j.transci.2014.11.005. 2015
Real World Bleeding Frequency in Patients with Inhibitors on Prophylaxis with Feiba: First Data Read-Out Of Feiba Global Outcome Study (FEIBA GO)
Escuriola-Ettingshausen, C; (...); Crea, R
Meeting Abstract. 2017
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megias-Vericata, J. E.; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2023.11.023. 2023
Real-world bleeding frequency in inhibitor patients on prophylaxis with apcc: data read-out of the "feiba global outcomes study (FEIBA GO)"
Ettingshausen, CE; (...); Crea, R
Meeting Abstract. 2018
Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with > 18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)
Windyga, Jerzy; (...); Escuriola, Carmen
Meeting Abstract. 10.1182/blood-2019-124324. 2019
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
Ettingshausen CE; (...); Windyga J
Article. 10.1177/20406207231184323. 2023
REAL-WORLD EFFICACY AND SAFETY DATA OF PATIENTS WITH HEMOPHILIA AND INHIBITORS TREATED WITH APCC: "FEIBA GLOBAL OUTCOME STUDY (FEIBA-GO)", RESULTS FROM > 12 MONTHS FOLLOW-UP
Windyga, J; (...); Escuriola-Ettinghausen, C
Meeting Abstract. 2019
RFVIIIFC FOR FIRST-TIME IMMUNE TOLERANCE INDUCTION (ITI) THERAPY: INTERIM RESULTS FROM THE GLOBAL, PROSPECTIVE VERITI-8 STUDY
Malec, L; (...); Peyvandi, F
Meeting Abstract. 2019
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors
Mancuso, ME; (...); European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal
Article. 10.1160/TH17-01-0059. 2017
Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project
Perez-Rodriguez, A; (...); Lopez-Fernandez, MF
Article. 10.1371/journal.pone.0197876. 2018
Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre
Article. 10.1111/vox.12066. 2014
Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors
Mingot-Castellano, ME; (...); Sedano-Balbas, C
Review. 10.1111/ejh.12730. 2016
Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors
Lopez-Fernandez, MF; (...); Balbas, CS
Article. 10.1160/TH15-07-0568. 2016
SWITCH ANALYSIS GUIDED BY PHARMACOKINETICS FROM FACTORS VIII OF STANDARD HALF LIFE TO EXTENDED HALF LIFE FACTORS
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Carcao, M; (...); Future Immunotolerance Treatment
Article. 10.1111/hae.13762. 2019
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
Gresele, P; (...); BAT-VAL Study Investigators
Article. 10.1111/jth.15263. 2021
THROMBIN GENERATION TEST IN PATIENTS UNDER NEW ORAL ANTICOAGULANTS (DABIGATRAN AND RIVAROXABAN)
Cabrera, N.; (...); Bonanad, S.
Meeting Abstract. 10.1016/S0049-3848(14)50148-X. 2014
Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project
Perez-Rodriguez, Almudena; (...); Lopez-Fernandez, Maria Fernanda
Article. 10.1111/hae.14405. 2021
Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA
Borras, N; (...); Corrales, I
Article. 10.3324/haematol.2018.203166. 2019
Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort
Borras, N; (...); Vidal, F
Article. 10.1055/s-0040-1702227. 2020
Until what age should we worry about inhibitors? New data from the PedNet Registry on 1,038 PUPs with severe hemophilia a followed from the first until over 1,000 exposure days
van den Berg, M; (...); PedNet Study Grp
Meeting Abstract. 2019
Update on Molecular Testing in von Willebrand Disease
Batlle, J; (...); PCM-EVW-ES Investigators Team
Review. 10.1055/s-0039-1679922. 2019
Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC.
Gresele P; (...); BAT-VAL study investigators
Article. 10.1111/jth.14683. 2020
Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations
Loomans, JI; (...); Fijnvandraat, K
Article. 10.1111/jth.13581. 2017